Peroxisome Proliferator-Activated Receptor δ and γ Agonists Differentially Alter Tumor Differentiation and Progression during Mammary Carcinogenesis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptor (PPAR) represents a ligand-dependent nuclear receptor family that regulates multiple metabolic processes associated with fatty acid β-oxidation, glucose utilization, and cholesterol transport. These and other receptor-mediated actions pertain to their role in hypolipidemic and antidiabetic therapies and as potential targets for cancer chemopreventive agents. The present study evaluated the chemopreventive activity of two highly potent and selective PPARγ and PPARδ agonists in a progestin- and carcinogen-induced mouse mammary tumorigenesis model. Animals treated with the PPARγ agonist GW7845 exhibited a moderate delay in tumor formation. In contrast, animals treated with the PPARδ agonist GW501516 showed accelerated tumor formation. Significantly, tumors from GW7845-treated mice were predominantly ductal adenocarcinomas, whereas tumors from GW501516-treated animals were adenosquamous and squamous cell carcinomas. Gene expression analysis of tumors arising from GW7845- and GW501516-treated mice identified expression profiles that were distinct from each other and from untreated control tumors of the same histopathology. Only tumors from mice treated with the PPARγ agonist expressed estrogen receptor-α in luminal transit cells, suggesting increased ductal progenitor cell expansion. Tumors from mice treated with the PPARδ agonist exhibited increased PPARδ levels and activated 3-phosphoinositide–dependent protein kinase-1 (PDK1), which co-associated, suggesting a link between the known oncogenic activity of PDK1 in mammary epithelium and PPARδ activation. These results indicate that PPARδ and PPARγ agonists produce diverse, yet profound effects on mammary tumorigenesis that give rise to distinctive histopathologic patterns of tumor differentiation and tumor development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“After the last dose of DMBA, mice were maintained on either a control diet or diets containing bioequivalent concentrations of either GW7845 or GW501516, based on their respective receptor affinities (35, 36), and the dose of GW7845 used previously (22).”
MethodChawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069 · cited 1×
“In interpreting the latter results, it is important to note that PPAR agonists of the thiazolidenedione class can act as partial agonists (24), exhibit dose-dependent biphasic activity (25), and act by receptor-independent mechanisms (27, 28, 42, 43).”
BackgroundHazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., & Tsukamoto, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310284200 · Cited by 320
Clay, C. E., Namen, A. M., Atsumi, G.-I., Trimboli, A. J., Fonteh, A. N., High, K. P., & Chilton, F. H. (2001) · Journal of Investigative Medicine · doi:10.2310/6650.2001.33786 · Cited by 67
Cited by
The role of COX‐2 in intestinal inflammation and colorectal cancer
Wang, D., & DuBois, R. N. (2010) · Oncogene · doi:10.1038/onc.2009.421 · Cited by 805
Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake
Merz, K. E., & Thurmond, D. C. (2020) · Comprehensive Physiology · doi:10.1002/cphy.c190029 · Cited by 494
Ondrey, F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0326 · Cited by 126
Upadhyay, G., Yin, Y., Yuan, H., Li, X., Derynck, R., & Glazer, R. I. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103441108 · Cited by 75
Self-citationKuriki, K., Wakai, K., Matsuo, K., Hiraki, A., Suzuki, T., Yamamura, Y., Yamao, K., Nakamura, T., Tatematsu, M., & Tajima, K. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0655 · Cited by 22
Metadata
- Authors
- Yin, Y., Russell, R. G., Dettin, L. E., Bai, R., Wei, Z.-L., Kozikowski, A. P., Kopleovich, L., & Glazer, R. I.
- Venue
- Cancer Research
- Published
- 2005-05-01
- Volume
- 65
- Issue
- 9
- Pages
- 3950-3957
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2114286828
- Cited by
- 101
- References
- 6
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peroxisome Proliferator-Activated Receptor δ and γ Agonists Differentially Alter Tumor Differentiation and Progression during Mammary Carcinogenesis. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-3990
- The paper
- Yin, Y., Russell, R. G., Dettin, L. E., Bai, R., Wei, Z.-L., Kozikowski, A. P., Kopleovich, L., & Glazer, R. I. (2005). Peroxisome Proliferator-Activated Receptor δ and γ Agonists Differentially Alter Tumor Differentiation and Progression during Mammary Carcinogenesis. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-3990
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.